Literature DB >> 16006759

The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation.

Chun-ming Cheung1, Tak-hong Tsoi, Chen-ya Huang.   

Abstract

BACKGROUND: Stroke prevention trials in patients with atrial fibrillation (AF) mainly studied the use of warfarin in Caucasians, and the international normalized ratio (INR) was targeted in the range of 2-4. The result may not necessarily be applicable to other ethnic groups. This study aimed to determine the optimal intensity of anticoagulation for stroke prevention in Chinese patients.
METHODS: We performed a retrospective study on all Chinese patients with AF taking warfarin for stroke prevention in our hospital from January 1, 2000, to June 30, 2002. Patients with a mechanical heart valve were excluded. We systematically studied their indication of using warfarin, duration of therapy and all INR results. Only those patients whose indications of using warfarin were consistent with the ACC/AHA/ESC Executive Summary were included. Thrombo-embolic episodes, sudden death, major bleeding, intracranial haemorrhage and the INR at the time of the event were recorded. The INR range was divided into six categories: <1.5, 1.5-1.9, 2.0-2.5, 2.6-3.0, 3.1-3.5, >3.5. The number of events was recorded for each category, and this formed the numerator. The denominator was the summation of time each patient stayed in each category of INR. The event rate was then calculated for each INR category.
RESULTS: 555 patients were included in the analysis, they constituted 893 patient-years. The INR was kept below 2.6 in 84.9% of the time and between 1.5 and 1.9 in 35% of the time. The overall event rate in our patients was 6.0%, of which 3.9% were due to thrombo-embolic events and 2.1% were due to serious bleeding. The overall event rate was lowest in the INR range from 1.5 to 1.9. which is not significantly different from that of INR 2.0-2.5 and 2.6-3.0. The overall event rate was 3.6% in INR 1.5-3.0 which was significantly lower than 15.1% in INR <1.5 and 20.5% in INR >3.0 (p < 0.01).
CONCLUSIONS: Our retrospective cohort showed that a lower INR range of 1.5-3.0 was safe and effective for stroke prevention in Chinese patients treated in a single hospital. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006759     DOI: 10.1159/000086801

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  10 in total

Review 1.  Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis.

Authors:  Natalie Oake; Alison Jennings; Alan J Forster; Dean Fergusson; Steve Doucette; Carl van Walraven
Journal:  CMAJ       Date:  2008-07-29       Impact factor: 8.262

Review 2.  Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage.

Authors:  Robert G Hart; Maria I Aguilar
Journal:  J Thromb Thrombolysis       Date:  2007-09-29       Impact factor: 2.300

3.  Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system.

Authors:  Shu-Wen Lin; Wen-Yi Kang; Dong-Tsamn Lin; James Lee; Fe-Lin Wu; Chuen-Liang Chen; Yufeng J Tseng
Journal:  BMC Med Genomics       Date:  2014-05-08       Impact factor: 3.063

Review 4.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

5.  Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.

Authors:  Elizabeth S Mearns; C Michael White; Christine G Kohn; Jessica Hawthorne; Ju-Sung Song; Joy Meng; Jeff R Schein; Monika K Raut; Craig I Coleman
Journal:  Thromb J       Date:  2014-06-24

6.  Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin.

Authors:  Sirote Luengsupabul; Komsing Methavigul; Ratikorn Methavigul
Journal:  J Arrhythm       Date:  2020-04-15

7.  The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation.

Authors:  Yi-Hsin Chan; Kuang-Tso Lee; Yi-Wei Kao; Chien-Ying Huang; Yung-Lung Chen; Samuel Chi-Ling Hang; Pao-Hsien Chu
Journal:  PLoS One       Date:  2019-03-18       Impact factor: 3.240

8.  Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?

Authors:  Dong Lin; Yequn Chen; Jian Yong; Shiwan Wu; Yan Zhou; Weiping Li; Xuerui Tan; Ruisheng Liu
Journal:  Front Cardiovasc Med       Date:  2021-11-25

Review 9.  Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies.

Authors:  Neil S Roskell; Miny Samuel; Herbert Noack; Brigitta U Monz
Journal:  Europace       Date:  2013-02-13       Impact factor: 5.214

10.  Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement.

Authors:  Jo-Ting Huang; Yi-Hsin Chan; Victor Chien-Chia Wu; Yu-Ting Cheng; Dong-Yi Chen; Chia-Pin Lin; Kuo-Chun Hung; Shang-Hung Chang; Pao-Hsien Chu; An-Hsun Chou; Shao-Wei Chen
Journal:  JAMA Netw Open       Date:  2022-02-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.